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Abstract
Background: Skin fibrosis is involved in a variety of pathologic conditions ranging from scar formation secondary to
surgery or trauma to immune-mediated processes. Skin fibrosis is a significant international health problem with an
estimated incidence of greater than 100 million people affected per year worldwide with few effective treatment
options available. Preliminary in vitro data generated by our research group suggests that red light can function as a
stand-alone treatment for skin fibrosis. To our knowledge, no prior clinical trials have been performed to determine the
safety of high-fluence (dose) light-emitting diode-red light (LED-RL) phototherapy. The goal of this study is to evaluate
the safety of LED-RL fluences from 160 J/cm2 up to 640 J/cm2 in healthy subjects.
Methods/design: This is a single-blind, dose escalation, randomized controlled, phase I study to evaluate the safety of
high-fluence LED-RL on human skin. The protocol for dose escalation requires subjects be enrolled sequentially in groups
of five. Within each group, three subjects will be randomized to LED-RL phototherapy and two subjects randomized to
mock therapy. Subjects in group 1 randomized to LED-RL phototherapy will receive the maximum recommended
starting dose (160 J/cm2). LED-RL dose will be escalated in subsequent groups (320 J/cm2, 480 J/cm2 and 640 J/cm2). The
maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible
toxicity and is considered to be the upper limit of subject tolerance. After either a MTD has been established, or the study
endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock
therapy subjects (for a total of 20) (determined randomly) will be enrolled. Each subject will receive a total of nine
procedures, three times per week for three consecutive weeks.
Discussion: This study may provide important safety information on the effects of high-fluence LED-RL phototherapy
on human skin and help facilitate future phase II studies to evaluate the efficacy of high-fluence LED-RL as a potential
noninvasive, safe, portable, at-home therapy for treatment of skin fibrosis.
Trial registration: ClinicalTrials.gov NCT02630303. Registered on 9 December 2015.
Keywords: Light-emitting diode-red light, LED-RL, High-fluence, Phototherapy, Skin fibrosis, Wound healing, Scar,
Keloid, RCT
* Correspondence: jrjagdeo@gmail.com
1Dermatology Service, Sacramento VA Medical Center, Mather, CA, USA
2Department of Dermatology, University of California Davis, Sacramento, CA,
USA
Full list of author information is available at the end of the article
© 2016 Ho et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ho et al. Trials  (2016) 17:385 
DOI 10.1186/s13063-016-1518-7
Background
Skin fibrosis is involved in a variety of pathologic condi-
tions ranging from scar formation secondary to surgery
or trauma, such as hypertrophic or keloid scars, to
immune-mediated processes, such as scleroderma and
chronic graft-versus-host disease. Skin fibrosis is a sig-
nificant international health problem with an estimated
incidence of greater than 100 million people affected per
year worldwide with few effective treatment options
available [1]. In addition, skin fibrosis is a significant so-
cioeconomic burden due to the functional, aesthetic, and
psychosocial impacts on patients’ lives [1, 2]. A con-
sumer survey of the American Society for Dermatologic
Surgery (ASDS) reported that over 50 % of survey re-
spondents considered treatment with laser and light
therapy to improve scar appearance and skin discolor-
ation [3]. In 2014, members of the ASDS performed
more than 2.7 million procedures using lasers, lights,
and energy-based devices [4]. Lasers and light-based de-
vices have gained increased attention and their use has
expanded amongst dermatologists and patients alike due
to minimal downtime associated with phototherapy pro-
cedures and convenient at-home use of many devices.
Many of the currently available treatments for skin
fibrosis have certain pitfalls and limitations. For ex-
ample, immunosuppressive agents such as systemic
corticosteroids may lead to serious systemic side
effects. Anti-fibrotic agents such as intralesional
steroids, 5-fluorouracil, and bleomycin are invasive,
painful, and have associated skin and systemic effects
[5–9]. Ultraviolet (UVA/UVA1) and UVB/narrowband
UVB phototherapy generate UV-induced deoxyribo-
nucleic acid (DNA) damage that is associated with
skin cancer and/or photoaging [10].
Recently published clinical observations indicate that
red light (600 to 700 nm) in combination with other mo-
dalities such as photosensitizers in combined red light
photodynamic therapy can lessen skin fibrosis [11–13].
Red light has a penetration depth of up to 4 mm, which
allows it to reach the entirety of the dermis where skin
fibrosis occurs [14, 15]. These findings make red light a
promising treatment modality that is noninvasive, un-
likely to cause systemic side effects, and does not gener-
ate pro-carcinogenic DNA damage as may occur in UV
light treatment.
Preliminary in vitro data generated by our research
group suggests that red light may function as a stand-
alone treatment for skin fibrosis, eliminating the side ef-
fects of chemical photosensitizers [16, 17]. Furthermore,
commercially available light-emitting diode-red light
(LED-RL) units exist and are already Food and Drug Ad-
ministration (FDA)-cleared for other dermatological uses
(such as for improvement of rhytides and acne) [18, 19].
Thus, clinical translation for the use of LED-RL
phototherapy in skin fibrosis could occur relatively
quickly following demonstration of its safety and effi-
cacy. Developing LED-RL phototherapy as a treatment
modality would represent an important advance in ther-
apy for scarring conditions, without the side effects asso-
ciated with current treatment options.
To our knowledge, no prior clinical trials have been per-
formed to determine the safety of high-fluence (dose)
LED-RL phototherapy. High-fluence LED-RL photother-
apy is phototherapy with fluence >160 J/cm2 per treat-
ment session. The goal of this study is to establish the
safety of LED-RL fluences from 160 J/cm2 up to 640 J/cm2
in healthy subjects, and to help facilitate future phase II ef-
ficacy studies of high-fluence LED-RL phototherapy as an
innovative, safe, and efficacious treatment modality.
Methods/design
Hypothesis
High-fluence LED-RL phototherapy is safe on human skin.
Study endpoints
This study will end if the maximally tolerated dose
(MTD) is identified or if the predefined study endpoint
of 640 J/cm2 is reached.
Study design and subject population
This is a single-blind, dose escalation, randomized
controlled, phase I study to evaluate the safety of high-
fluence LED-RL phototherapy on human skin. The max-
imum recommended starting dose (MRSD) of 160 J/cm2
is based upon previously published maximum doses of
LED-RL phototherapy used in clinical studies that dem-
onstrated clinical safety with no adverse events [18, 19].
The study endpoint of 640 J/cm2 was chosen due to
feasibility, as this dose corresponds to 2 hours of LED-
RL phototherapy, and we anticipate decreased subject
compliance with LED-RL exposures longer than 2 hours
in duration. Additionally in prior studies, the 640 J/cm2
dose demonstrated increased anti-fibrotic properties in
vitro compared to lower doses of LED-RL [17].
The protocol for dose escalation requires subjects to
be enrolled sequentially in groups of five (three subjects
randomized to LED-RL phototherapy and two subjects
randomized to mock therapy). As this is a single-blind
study, subjects will be blinded to the procedure (LED-RL
phototherapy or mock therapy).
Subjects in group 1 randomized to LED-RL photother-
apy will receive the MSRD of 160 J/cm2. The LED-RL
dose will be escalated in subsequent groups using the
classical method for dose escalation as described by
Spilker: starting with dose (X) increased by an equal
amount (in this instance: X = 160 J/cm2, 2X = 320 J/cm2,
3X = 480 J/cm2, and 4X = 640 J/cm2) [20]. Common ex-
pected procedural side effects are mild and are expected
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to last less than 24 hours, which include warmth, redness
(erythema), and swelling (edema). The MTD is defined as
the dose level below the dose producing unacceptable but
reversible toxicity and is considered to be the upper limit
of subject tolerance. Unacceptable but reversible toxicities
(adverse events) for this study include: second-degree or
higher skin burning or blistering, erythema lasting more
than 24 hours, severe swelling, pain, ulceration, change in
sensation, and/or muscle weakness. If one or more subject
experiences any of these adverse events, then this is the
dose one above the MTD, and we will not proceed with
this dose or escalate the dose.
After either an MTD has been established, or the
study endpoint of 640 J/cm2 has been achieved, an add-
itional 27 LED-RL phototherapy subjects (for a total of
30) and 18 mock therapy subjects (for a total of 20) (de-
termined randomly) will be enrolled to satisfy Hanley’s
Rule of Three, such that it can be concluded with 95 %
confidence that fewer than 1 person in 10 will experi-
ence an adverse event [21]. Of the larger cohort, the
study will be stopped if adverse events determined to be
device-related equal or exceed 30 %. Each subject will
receive a total of nine LED-RL phototherapy or mock
therapy procedures, three times per week for three con-
secutive weeks. The phototherapy regimen of three pro-
cedures per week is a standard phototherapy protocol
[22]. Each subject will receive a US$50 check for com-
pletion of 1 week (total of US$150 for completion of en-
tire study), and subjects will receive a prorated amount
in the event of withdrawal from study.
This study has a sample size of up to 65 subjects. Sub-
jects will be recruited from the Sacramento Veterans Af-
fairs (VA) Medical Center. As detailed in the inclusion
criteria, subjects may be of any sex, age, and ethnicity. The
Standard Protocol Items: Recommendations for Interven-
tional Trials (SPIRIT) checklist, flow diagram, and trial
registration data are available as Additional files 1, 2, and 3.
Inclusion and exclusion criteria
Please refer to Table 1 for a listing of study inclusion
and exclusion criteria. All subjects will be tested for
photosensitivity as per the manufacturer’s user guide in-
structions. A 20-minute session of LED-RL phototherapy
will be performed on the subject’s nondominant prox-
imal anterior forearm, and evaluation for photosensitiv-
ity will occur 24 hours post LED-RL phototherapy.
Criteria for photosensitivity include but are not limited
to: warmth, erythema (redness), edema (swelling), rash,
pain, or discomfort lasting more than 24 hours.
Specifications of LED-RL phototherapy and mock
therapy hand-held unit
The LED-RL light source is a commercially available
Omnilux New-U hand-held LED-RL phototherapy unit
(provided by Photo Therapeutics, Carlsbad, CA, USA),
and is FDA-cleared for treatment of periorbital rhytides
(crow’s feet) and may be placed in direct contact with
the skin [23]. The mock therapy unit, also provided by
Photo Therapeutics, Carlsbad, CA, USA, only generates
warmth and does not emit LED-RL. The LED has a
4.7 cm × 6.1 cm rectangular aperture and emits visible
red light (633 nm ± 30 nm) at a power density of
360.2 W/m2 at room temperature in direct contact with
the photometer.
Study procedure
The study procedure for subjects receiving LED-RL
phototherapy and for subjects receiving mock therapy is
identical with the exception of utilizing the LED-RL
phototherapy unit or the mock therapy unit for the ran-
domized subjects in their respective groups. After con-
firming subject identity, screening for study eligibility,
and obtaining written Institutional Review Board (IRB)-
approved informed consent, the subject will be taken to
a private clinic examination room at the Dermatology
Clinic in Sacramento VA Medical Center. The subject’s
nondominant proximal anterior forearm will be cleaned
with alcohol pads. A surgical marking pen will be used
to outline the procedure area at the start and completion
of every visit. The LED-RL phototherapy or mock ther-
apy hand-held unit will be held in place and in direct
contact with the clean area using nonadhesive tape
(ACE elastic bandage or similar) during the procedure.
All subjects will be provided with protective eyewear to
use at LED-RL phototherapy and mock therapy sessions.
The research team will be observing the procedure and
assessing for any safety issues during and immediately
post-procedure. Photographs will be taken pre-and post-
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Healthy subjects of any
sex, age, and ethnicity
• Nondominant proximal
anterior forearm is wide
enough to ensure
reproducible placement
of light-emitting diode-red
light (LED-RL) phototherapy
or mock therapy
hand-held unit
• Available and willing to
attend all clinic visits
• Able and willing to give
informed consent
• Subjects on any photosensitizing
medications (i.e. lithium, melatonin,
phenothiazine antipsychotics, antibiotics)
• Subjects with light-sensitive conditions
• Subjects with diabetes mellitus (DM)
• Subjects with a history of skin cancer:
basal cell carcinoma (BCC), squamous
cell carcinoma (SCC), or melanoma
• Subjects with systemic lupus
erythematosus (SLE)
• Subjects with any other medical
condition that could be compromised
by exposure to the proposed procedure
• Subjects with open wounds on the
nondominant proximal anterior forearm
• Subjects with fibrotic skin disease or
other skin conditions on the
nondominant proximal anterior forearm
• Subjects with tattoos that cover the
procedure site on the nondominant
proximal anterior forearm
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procedure at each clinic visit to record and assess for
common expected procedural side effects and adverse
events, and to ensure uniformity of procedure location
at every clinic visit.
Safety assessment
All subjects will be asked to record any common ex-
pected procedural side effects and adverse events in a
subject diary of adverse events for the entire duration of
study participation. A review of the subject’s diary will
occur at each clinic visit prior to the start of the proced-
ure. Subjects will be called weekly to monitor for any ad-
verse events. Subjects with adverse events will receive
standard medical care outside of the scope of this study.
Ancillary and post-study care is available at the General
Dermatology Clinic, Sacramento VA Medical Center, but
no additional compensation will be provided to those
who suffer harm from study participation. All common
expected procedural side effects and adverse events will
be described in the Case Report Form. The Data Safety
Monitoring Board, which includes three board-certified
dermatologists, one phototherapy nurse, and two clinical
research coordinators, will convene monthly to review
and assess any study safety issues. The principal investi-
gator (PI: JJ) has access to interim results and may make
the decision to stop a subject from study participation
due to safety reasons.
Randomization
Randomization will be performed by clinical research
coordinators via the www.randomizer.org website. For
assignment of study groups, Arabic numerals “1,” “2,”
“3,” “4,” and “5” will be generated at random. Subjects
assigned to “1” will be in group 1 (160 J/cm2), “2” will be
in group 2 (320 J/cm2), “3” will be in group 3 (480 J/
cm2), “4” will be in group 4 (640 J/cm2), and “5” will be
in group 5 (640 J/cm2 or MTD). For assignment of LED-
RL phototherapy and mock therapy, Arabic numerals
“1” and “2” will be generated at random. Subjects
assigned to “1” will receive LED-RL phototherapy and
subjects assigned to “2” will receive mock therapy. A
study randomization flowchart is shown in Fig. 1.
Blinding
This is a single-blind study, and the subjects will be
blinded to the procedure (LED-RL phototherapy or
mock therapy). The PI and clinical research coordinators
(DH and EK) will be aware of the randomization.
Time frame
This study is designed to conclude in 7 months, which
includes subject recruitment, performing procedures
with LED-RL phototherapy and mock therapy, and data
analysis.
Statistical analysis
Statistical analysis will be performed using Statistical
Package for Social Sciences (SPSS) or similar. Quantita-
tive data will be presented as mean ± standard deviation
and range while qualitative data will be presented as
number (n) and percentage (%). Student’s t test will be
used to determine if there is a significant difference in
the rate of common expected procedural side effects and
adverse events between the LED-RL phototherapy group
and the mock therapy group. P <0.05 will be used as sta-
tistically significant. Data analysis relating to protocol
nonadherence and any missing data will be consulted
with the biostatistics service at UC Davis Clinical and
Translational Science Center.
Discussion
To our knowledge, no prior clinical trials have been per-
formed to determine the safety of high-fluence LED-RL
phototherapy. This study may provide important safety
information on high-fluence LED-RL phototherapy
(160 J/cm2 up to 640 J/cm2) and help facilitate future
phase II studies to evaluate the efficacy of high-fluence
LED-RL as a potential noninvasive, safe, portable, at-
home therapy for treatment of skin fibrosis. In addition,
future phase II clinical trials may reference this study to
determine an optimal dose of LED-RL phototherapy for
treatment of skin fibrosis.
There may be several potential limitations of this
study, which may be encountered at the Sacramento VA
Medical Center, Mather, CA, USA. There may be bias
towards the male sex in a veteran population, with
women representing only 9 % of veterans nationwide
[24]. Men have more skin collagen and thicker skin in
comparison to women [25], and thus may require higher
doses of LED-RL to produce an adverse event. Thus, the
MTD of LED-RL phototherapy may differ between men
and women. In addition, there may be bias in age toward
middle-aged and elderly subjects recruited within the
veteran population. Since increased age is associated
with reduced skin collagen [26], the penetration of LED-
RL may be affected, and the total dose that results in an
adverse event may vary amongst different age groups.
Consequently, the MTD obtained from this study may
only be representative for the sampled age groups. Fur-
thermore, there is bias in ethnicity toward Caucasians
within the veteran population, with the minority of vet-
erans nationwide being represented by approximately
12 % African Americans, 7 % Hispanics, and 4 % other
ethnicities [24]. The research team will attempt to
minimize bias by approaching and recruiting subjects of
any sex, age, and ethnicity.
To our knowledge, this is the first phase I clinical trial
investigating high-fluence LED-RL on human skin.
Therefore, we are conducting a single-site clinical trial.
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Fig. 1 (See legend on next page.)
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This phase I study was designed with consultation from
the Clinical and Translational Science Center (CTSC)
Biostatistics and Bioethical services. Randomization and
recruitment of a variety of subjects will help minimize
bias. Limited data exists pertaining to LED-RL safety
and effect in different Fitzpatrick skin types or pigmen-
tation. Post-phase I trial statistical analysis will deter-
mine differential safety of LED-RL associated with race
and ethnicity and examine to see whether this should be
further pursued using more subjects with greater power
in a future study, or dose stratification based upon pig-
mentation. Future multicenter phase I studies stratifying
race and ethnicity can be done to determine whether dif-
ferent skin types have different MTDs.
Future phase II studies may evaluate the efficacy of
high-fluence LED-RL phototherapy as a potential treat-
ment modality for skin fibrosis based upon the safety in-
formation obtained from this study. Following successful
demonstration of the safety of high-fluence LED-RL
phototherapy on human skin, our research group may
pursue a phase II split-scar study to evaluate the efficacy
of high-fluence LED-RL phototherapy. Successful dem-
onstration of the efficacy of high-fluence LED-RL photo-
therapy for treatment of skin fibrosis has the potential to
benefit many individuals worldwide, as high-fluence
LED-RL phototherapy may lack the side effects that are
associated with currently available treatment options.
Study status
This study began enrolling subjects in January 2016 at
the Sacramento VA Medical Center, Mather, CA, USA.
Additional files
Additional file 1: SPIRIT checklist. (PDF 502 kb)
Additional file 2: SPIRIT flow diagram. (DOC 50 kb)
Additional file 3: SPIRIT trial registration data. (DOCX 110 kb)
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Fig. 1 Study randomization flowchart. The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable
but reversible toxicity and is considered the upper limit of subject tolerance. Unacceptable but reversible toxicities (adverse events) for this study
include: second-degree or higher skin burning or blistering, erythema lasting more than 24 hours, severe swelling, pain, ulceration, change in
sensation, and/or muscle weakness
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